TY  - JOUR
AU  - Kroll, Tina
AU  - Elmenhorst, David
AU  - Matusch, Andreas
AU  - Wedekind, Franziska
AU  - Weißhaupt, Angela
AU  - Beer, Simone
AU  - Bauer, Andreas
TI  - Suitability of [18F]Altanserin and PET to Determine 5-HT2A Receptor Availability in the Rat Brain: In Vivo and In Vitro Validation of Invasive and Non-Invasive Kinetic Models
JO  - Molecular imaging & biology
VL  - 15
IS  - 4
SN  - 1860-2002
CY  - Amsterdam [u.a.]
PB  - Elsevier Science
M1  - FZJ-2013-02758
SP  - 456-467
PY  - 2013
AB  - PURPOSE: While the selective 5-hydroxytryptamine type 2a receptor (5-HT2AR) radiotracer [(18)F]altanserin is well established in humans, the present study evaluated its suitability for quantifying cerebral 5-HT2ARs with positron emission tomography (PET) in albino rats. PROCEDURES: Ten Sprague Dawley rats underwent 180 min PET scans with arterial blood sampling. Reference tissue methods were evaluated on the basis of invasive kinetic models with metabolite-corrected arterial input functions. In vivo 5-HT2AR quantification with PET was validated by in vitro autoradiographic saturation experiments in the same animals. RESULT: Overall brain uptake of [(18)F]altanserin was reliably quantified by invasive and non-invasive models with the cerebellum as reference region shown by linear correlation of outcome parameters. Unlike in humans, no lipophilic metabolites occurred so that brain activity derived solely from parent compound. PET data correlated very well with in vitro autoradiographic data of the same animals. CONCLUSION: [(18)F]Altanserin PET is a reliable tool for in vivo quantification of 5-HT2AR availability in albino rats. Models based on both blood input and reference tissue describe radiotracer kinetics adequately. Low cerebral tracer uptake might, however, cause restrictions in experimental usage.
LB  - PUB:(DE-HGF)16
C6  - pmid:23456885
UR  - <Go to ISI:>//WOS:000321972500013
DO  - DOI:10.1007/s11307-013-0621-3
UR  - https://juser.fz-juelich.de/record/134641
ER  -